SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?


To: Henry Niman who wrote (5655)11/9/1998 6:40:00 PM
From: Biomaven  Read Replies (1) | Respond to of 6136
 
Henry,

First payoff from the proposed spin-off? Interesting that Elise Wang's price target is derived from a reasonable looking 25 PE multiple on AGPH general only. It would have had to be a much higher multiple on the consolidated company.

In other words, as I predicted it would, the spin-off is having a concrete (favorable) effect on the way analysts view the company.

Peter